Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | TLR4 | O00206 | 10/20 | 0.57 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15333976 | 1.00 | LMNA (0.61) | LMNATLR4LY96KMT2APOLB | |
| SCHEMBL30718114 | 0.95 | LMNA (0.63) | LMNATLR4LY96KMT2APOLB | |
| SCHEMBL31540817 | 0.92 | TLR4 (0.59) | LMNATLR4LY96KMT2APOLB | |
| SCHEMBL25957762 | 0.91 | LMNA (0.65) | LMNATLR4KMT2APOLBALDH1A1 | |
| SCHEMBL30032874 | 0.91 | LMNA (0.65) | LMNATLR4KMT2APOLBALDH1A1 | |
| SCHEMBL21138671 | 0.91 | LMNA (0.65) | LMNATLR4KMT2APOLBALDH1A1 | |
| SCHEMBL21058368 | 0.91 | LMNA (0.65) | LMNATLR4KMT2APOLBALDH1A1 | |
| SCHEMBL9519945 | 0.91 | LMNA (0.51) | LMNATLR4LY96KMT2APOLB | |
| SCHEMBL10961698 | 0.88 | LMNA (0.48) | LMNATLR4LY96KMT2APOLB | |
| SCHEMBL10961699 | 0.88 | LMNA (0.48) | LMNATLR4LY96KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019055597-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TSC | National Tuberous Sclerosis Association, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077874-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS | National Tuberous Sclerosis Association, Inc. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077874-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS | TLR4, TLR3, TLR2 | LMNA 1227/4885TLR4 1/4885LY96 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.